Literature DB >> 23880147

Are prognostic factors more favorable for breast cancer detected by organized screening than by opportunistic screening or clinical diagnosis? A study in Loire-Atlantique (France).

Antoine Vanier1, Christophe Leux, Corinne Allioux, Solenne Billon-Delacour, Pierre Lombrail, Florence Molinié.   

Abstract

PURPOSE: Comparisons of breast cancer characteristics between organized and opportunistic screening have been limited. This study was designed to compare characteristics of cancers detected by either organized or opportunistic screening as well as clinically diagnosed cancers in Loire-Atlantique (a French administrative entity), from 2003 to 2007.
METHODS: This study is based on data from the population-based Loire-Atlantique Cancer Registry. Stage at diagnosis and prognostic characteristics of carcinomas detected by organized screening were compared, by age-adjusted logistic regressions, to those of cancers detected by opportunistic screening and diagnosed clinically. Analyses were restricted to women aged 50-74 years (the age group targeted by the organized screening program) for the 2003-2007 period.
RESULTS: Between 2003 and 2007, 2864 invasive and 400 in situ breast cancer cases were diagnosed in women aged 50-74 years in Loire-Atlantique. Compared to cancers diagnosed clinically, cancers detected by organized screening were more likely to be in situ (13.7% vs. 3.8%), diagnosed at an early stage (74.4% vs. 51.3%), have a low SBR grade (grade 1: 35.4% vs. 18.5%), and be positive for estrogen-progesterone receptors (68.3% vs. 59.0%). The distribution of stage at diagnosis and prognostic characteristics between organized and opportunistic screening were similar.
CONCLUSION: These findings are consistent with the hypothesis that breast cancers are detected early by organized screening. Cancer characteristics were similar between the two screening modes. Estimating the impact of mammography screening on mortality in Loire-Atlantique should be the object of further investigations.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast neoplasm; Epidemiology; Mammography; Opportunistic screening; Organized screening

Mesh:

Year:  2013        PMID: 23880147     DOI: 10.1016/j.canep.2013.07.001

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  5 in total

1.  Ultrasound as the Primary Screening Test for Breast Cancer: Analysis From ACRIN 6666.

Authors:  Wendie A Berg; Andriy I Bandos; Ellen B Mendelson; Daniel Lehrer; Roberta A Jong; Etta D Pisano
Journal:  J Natl Cancer Inst       Date:  2015-12-28       Impact factor: 13.506

2.  Biennial screening mammography: How many women ask for more? Estimate of the interval mammogram rate in an organised population-based screening programme.

Authors:  Luca Alessandro Carbonaro; Sighelgaita Sonia Rizzo; Simone Schiaffino; Anna Pisani Mainini; Nicole Berger; Rubina Manuela Trimboli; Francesco Sardanelli
Journal:  Radiol Med       Date:  2020-06-23       Impact factor: 3.469

3.  Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.

Authors:  Gautier Defossez; Alexandre Quillet; Pierre Ingrand
Journal:  BMC Cancer       Date:  2018-04-06       Impact factor: 4.430

4.  Differences in breast cancer-risk factors between screen-detected and non-screen-detected cases (MCC-Spain study).

Authors:  Marta Hernández-García; Ana Molina-Barceló; Mercedes Vanaclocha-Espi; Óscar Zurriaga; Beatriz Pérez-Gómez; Nuria Aragonés; Pilar Amiano; Jone M Altzibar; Gemma Castaño-Vinyals; María Sala; María Ederra; Vicente Martín; Inés Gómez-Acebo; Carmen Vidal; Adonina Tardón; Rafael Marcos-Gragera; Marina Pollán; Manolis Kogevinas; Dolores Salas
Journal:  Cancer Causes Control       Date:  2021-11-24       Impact factor: 2.506

5.  Increased breast cancer screening and downstaging in Colombian women: A randomized trial of opportunistic breast-screening.

Authors:  Raúl Murillo; Sandra Díaz; Fernando Perry; César Poveda; Marion Piñeros; Oswaldo Sánchez; Lina Buitrago; Oscar Gamboa; Teófilo Lozano; Hsiang Yu; Ching-Yun Wang; Catherine Duggan; David B Thomas; Benjamin O Anderson
Journal:  Int J Cancer       Date:  2015-09-02       Impact factor: 7.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.